|
WO2020235974A2
|
|
Single base substitution protein, and composition comprising same
|
|
KR20200123392A
|
|
A Composition for inhibiting Hepatitis B virus proliferation and its method
|
|
WO2020197330A1
|
|
Composition for treating hemophilia by means of blood coagulation factor viii gene inversion correction
|
|
WO2020197242A1
|
|
Hemophilia b rat model
|
|
US2020199617A1
|
|
Artificial genome manipulation for gene expression regulation
|
|
KR20200049594A
|
|
Manipulated immune cell
|
|
WO2020022802A1
|
|
Genome editing for treating autoimmune disease
|
|
WO2020022803A1
|
|
Gene editing of anticoagulants
|
|
WO2020218657A1
|
|
Target specific crispr mutant
|
|
KR20200125191A
|
|
Target Specific CRISPR variants
|
|
WO2019147073A1
|
|
Method for identifying base editing by using adenosine deaminase
|
|
US2020263204A1
|
|
Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion
|
|
KR20190038407A
|
|
Genome editing for treating Retinal dysfunction disease
|
|
SG11202002130WA
|
|
Artificial genome manipulation for gene expression regulation
|
|
CA3069296A1
|
|
Target-specific crispr mutant
|
|
WO2018236131A1
|
|
Angiopoietin-1- or vegf-secreting stem cell and pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising same
|
|
CA3067316A1
|
|
Platform for expressing protein of interest in liver
|
|
KR20180136905A
|
|
A system for genome editing toward repeat expansion mutation
|
|
KR20200001596A
|
|
Artificially engineered immune cells
|
|
KR20200021449A
|
|
Pharmaceutical composition for preventing or treating neurological diseases or cardiovascular diseases including stem cells secreting sRAGE
|
